Lu-177-PSMA-ALB-56
177Lu-PSMA-ALB-56 is a radiolabeled PSMA analogue developed for prostate cancer [...]
177Lu-PSMA-ALB-56 is a radiolabeled PSMA analogue developed for prostate cancer [...]
177Lu-Ludotadipep (177Lu-FC705) is a 177Lu-labeled analogue of 177Lu-Vipivotide targeting PSMA. [...]
161Tb-PSMA-I&T is a terbium analogue of 177Lu-Vipivotide tetraxetan and the [...]
rhPSMA (radiohybrid PSMA) is a prostate specific membrane antigen labeled [...]
177Lu-Rosopatamab (177Lu-J591, 177Lu-TLX591, 177Lu-J591, 177Lu-ATL-101) is the Lutetium-177 labeled [...]
177Lu-Vipivotide tetratexan (177Lu-PSMA-617) is a 177Lu labeled peptide developed [...]
225Ac-PSMA-617 is the next generation of prostate cancer treatment following [...]
177Lu-iPSMA is the therapeutic analogue of 99mTc-iPSMA developed at [...]
227Th-Pelgifatamab(227Th-PSMA-TTC, 227Th-BAY2315497) is a Thorium-227 labelled PSMA-targeted full IgG antibody [...]
177Lu-EB-PSMA-617 is a PSMA-617 analogue developed in China as an [...]